Serum YKL-40 has also been reported to be associated with SAP in our previous study, which was a strong factor influencing clinical outcomes of AIS patients, and patients with SAP have a higher risk of poor functional outcome [8, 11]. The gene discussed is CHI3L1; the disease is androgen insensitivity syndrome.